# Cardiff Oncology, Inc.: overview CRDF · Nasdaq · CIK 1213037 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crdf.md) · [Financials](/companies/crdf/financials.md) · [Filings](/companies/crdf/filings.md) · [Insiders](/companies/crdf/insiders.md) Latest reported revenue: [$104.0k](/filings/0001193125-26-344545.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344545). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001193125-25-269424.md) | [0.2 d](/filings/0001193125-26-067464.md) | [0.1](/filings/0001213037-26-000011.md) | [0.1](/filings/0001193125-26-344545.md) | [0.1](/filings/0001193125-25-269424.md) | [0.2 d](/filings/0001193125-26-067464.md) | [0.0](/filings/0001213037-26-000011.md) | [0.1](/filings/0001193125-26-344545.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(7637.0%)](/filings/0001193125-25-269424.md) | [(8325.8%) d](/filings/0001193125-26-067464.md) | [(13194.5%)](/filings/0001213037-26-000011.md) | [(12212.4%)](/filings/0001193125-26-344545.md) | [(9978.3%)](/filings/0001193125-25-269424.md) | [(3221.0%) d](/filings/0001193125-26-067464.md) | [(31341.5%)](/filings/0001213037-26-000011.md) | [(9245.2%)](/filings/0001193125-26-344545.md) | | Net margin | % | [(7184.8%)](/filings/0001193125-25-269424.md) | [(7806.0%) d](/filings/0001193125-26-067464.md) | [(12324.8%)](/filings/0001193125-26-344545.md) | [(11523.1%)](/filings/0001193125-26-344545.md) | [(9381.7%)](/filings/0001193125-25-269424.md) | [(2969.5%) d](/filings/0001193125-26-067464.md) | [(30109.8%)](/filings/0001193125-26-344545.md) | [(8876.9%)](/filings/0001193125-26-344545.md) | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-269424.md) | not reported | [(0.20)](/filings/0001213037-26-000011.md) | [(0.21)](/filings/0001193125-26-344545.md) | [(0.17)](/filings/0001193125-25-269424.md) | not reported | [(0.18)](/filings/0001213037-26-000011.md) | [(0.14)](/filings/0001193125-26-344545.md) | | Free cash flow | $m | [(10.5) d](/filings/0001193125-25-269424.md) | [(10.3) d](/filings/0001193125-26-067464.md) | not reported | not reported | [(10.9) d](/filings/0001193125-25-269424.md) | [(6.0) d](/filings/0001193125-26-067464.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.4](/filings/0001628280-23-006037.md) | [0.4](/filings/0001628280-24-007948.md) | [0.5](/filings/0000950170-25-028992.md) | [0.7](/filings/0001193125-26-067464.md) | [0.6](/filings/0001193125-26-067464.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(8037.6%)](/filings/0001628280-23-006037.md) | [(10337.3%)](/filings/0001628280-24-007948.md) | [(9305.7%)](/filings/0000950170-25-028992.md) | [(7123.1%)](/filings/0001193125-26-067464.md) | [(8256.3%)](/filings/0001193125-26-067464.md) | | Net margin | % | [(7880.5%)](/filings/0001628280-23-006037.md) | [(10026.9%)](/filings/0001628280-24-007948.md) | [(8492.0%)](/filings/0000950170-25-028992.md) | [(6651.7%)](/filings/0001193125-26-067464.md) | [(7732.0%)](/filings/0001193125-26-067464.md) | | Diluted EPS | $ per share | [(0.73)](/filings/0001628280-23-006037.md) | [(0.89)](/filings/0001628280-24-007948.md) | [(0.93)](/filings/0000950170-25-028992.md) | [(0.95)](/filings/0001193125-26-067464.md) | [(0.69)](/filings/0001193125-26-067464.md) | | Free cash flow | $m | [(23.2)](/filings/0001628280-23-006037.md) | [(34.8)](/filings/0001628280-24-007948.md) | [(31.5)](/filings/0000950170-25-028992.md) | [(37.8)](/filings/0001193125-26-067464.md) | [(38.0)](/filings/0001193125-26-067464.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crdf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $4.0m | 3,098,299 | | Added +451,561 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.8m | 2,895,592 | | Added +39,626 | | [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $3.0m | 2,411,575 | | Unchanged | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $1.6m | 1,205,803 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.3m | 972,873 | | Reduced −3,008,514 | | [BLAIR WILLIAM & CO/IL](/funds/902367.md) | 2026-06-30 | $1.2m | 912,513 | | Reduced −9,894 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.1m | 820,062 | | Reduced −779,601 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $830.3k | 638,699 | | Added +238,123 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $790.3k | 607,900 | | Added +567,795 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $533.8k | 410,602 | | Reduced −35,623 | ## Recent filings [All 1,047 filings](/companies/crdf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 16:44 ET | [8-K](/filings/0001493152-26-048720.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-048720 | | 2026-10-22 | 16:30 ET | [8-K](/filings/0001493152-26-048111.md) | 5.07 Shareholder vote results | 0001493152-26-048111 | | 2026-09-14 | 09:28 ET | [8-K](/filings/0001493152-26-042506.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042506 | | 2026-08-26 | 16:01 ET | [DEF 14A](/filings/0001193125-26-368249.md) | Proxy statement, period 2026-08-26 | 0001193125-26-368249 | | 2026-08-11 | 16:11 ET | [8-K](/filings/0001193125-26-344645.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344645 | | 2026-08-11 | 16:01 ET | [10-Q](/filings/0001193125-26-344545.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344545 | | 2026-07-16 | 08:38 ET | [8-K](/filings/0001193125-26-305467.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-305467 | | 2026-06-11 | 16:15 ET | [8-K](/filings/0001193125-26-267563.md) | 5.07 Shareholder vote results | 0001193125-26-267563 | | 2026-06-03 | 08:30 ET | [8-K](/filings/0001193125-26-254658.md) | 7.01 Regulation FD disclosure | 0001193125-26-254658 | | 2026-05-29 | 17:11 ET | [8-K](/filings/0001193125-26-248711.md) | 1.01 Entry into a material agreement | 0001193125-26-248711 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-067464.md), filed Feb 24, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/082262e3-357c-4d47-afa4-69a0eb526c67) ## About the filer - CIK: 1213037 - Tickers: CRDF - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:47 ET. No prices; not investment advice.